马骏

中国科学院院士，教授
中山大学

报告题目：以临床问题为导向开展科技创新：在项目中培养青年人才、锻造有国际竞争力团队

马骏，中国科学院院士，中山大学肿瘤防治中心常务副主任、常务副院长。担任国务院学位委员会特种医学学科评议组召集人、第八届教育部科学技术委员会生命医学部委员、中国临床肿瘤学会(CSCO)鼻咽癌专业委员会主任委员、中国抗癌协会(CACA)鼻咽癌专业委员会主任委员等。

主要研究方向为鼻咽癌的精准诊治，提出了鼻咽癌临床分期诊断国际新标准，创立了晚期鼻咽癌化疗联合放疗增效新方案及低风险鼻咽癌的减毒治疗新策略，领导制定了《中-美临床肿瘤学会鼻咽癌诊治国际指南》，指导了全球的临床实践，实现了我国鼻咽癌诊疗水平从跟跑到领跑的跨越。

作为最后/唯一通讯作者在国际医学顶尖刊物发表论著如CA、NEJM、Lancet(3篇)、JAMA(2篇)、BMJ(2篇)、Nat Med、Cancer Cell(2篇)、Lancet Oncology(5篇)、 JCO等。作为第一完成人获国家科技进步二等奖三项(2009、2015、2023)。获得何梁何利基金科学与技术进步奖、吴阶平医药创新奖、谈家祯生命科学奖及首届全国创新争先奖状等奖项。他指导的多名研究生获得国家高层次人才，如长江特聘（2人）、国家杰青、优青（2人）及青年长江学者等6人，带领团队入选“教育部创新团队发展计划、科技部重点领域创新团队及国家外专局/教育部高等学校创新引智基地”。

Ma Jun, Academician of the Chinese Academy of Sciences, Executive Vice-president of Sun Yat-sen University Cancer Center, convener of the Discipline Evaluation Group for Special Medicine of the Academic Degrees Committee of the State Council, Member of the 8th Science and Technology Committee in the field of Life Sciences and Medicine of the Ministry of Education, the Chairman of the Nasopharyngeal Carcinoma Committee of the Chinese Society of Clinical Oncology (CSCO), Chairman of the Society of Nasopharyngeal Carcinoma of the Chinese Anti-Cancer Association (CACA).

Prof. Ma's research focuses on the precise diagnosis and treatment of nasopharyngeal carcinoma (NPC). He has proposed international standards for the clinical staging diagnosis of NPC, pioneered novel radiochemotherapy schemes to enhance efficacy in advanced NPC, and introduced a “de-intensification” treatment strategy for low-risk NPC. Furthermore, he led the development of “Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline”. It provides clinical guidance worldwide and has significantly improved China's NPC diagnosis and treatment capabilities, positioning them as a leader on the global stage.

As the corresponding author, he has published numerous high-level papers in prestigious journals like CA，NEJM, Lancet, JAMA, BMJ, Nat Medicine, Cancer Cell, Lancet Oncol, J Clinc Oncol. His achievements have garnered prestigious accolades including the "State Scientific and Technological Progress Award", "Chinese Medical Science and Technology Award", "University Scientific , etc.

Selected Publications Over the Past 5 Years:

1. Tang LL, Chen L, Xu GQ, Zhang N, Huang CL, Li WF, Mao YP, Zhou GQ, Lei F, Chen LS, Huang SH, Chen L, Chen YP, Zhang Y, Liu X, Xu C, Zhao Z, Li JB, Liu N, Xie FY, Guo R, Sun Y, Ma J (Corresponding author). Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial. CA Cancer J Clin. 2025;1–13. (IF 503.1)
2. Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, He ZY, Chen NY, Hu WH, Wu HJ, Shi M, Zhou GQ, Mao YP, Guo R, Sun R, Huang J, Liang SQ, Wu WL, Su Z, Li L, Ai P, He YX, Zang J, Chen L, Lin L, Huang SH, Xu C, Lv JW, Li YQ, Hong SB, Jie YS, Li H, Huang SW, Liang YL, Wang YQ, Peng YL, Zhu JH, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Lin AH, Li JB, Liu N, Tang LL, Chen YP, Sun Y, Ma J (Corresponding author). Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet, 2024, 403(10445): 2720-2731. (IF 98.4)
3. Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, Shi M, Hu GQ, Hu WH, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL, Xie FY, Sun Y, Ma J (Corresponding author). Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10297):303-313. (IF 98.4)
4. Mao YP, Wang SX, Gao TS, Zhang N, Liang XY, Xie FY, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL, Chen L, Sun Y, Ma J (Corresponding author). Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023;380:e072133. (IF 93.6)
5. Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y, Ma J (Corresponding author). Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA. 2022;328(8):728-736. (IF 63.1)
6. Lv J, Wei Y, Yin JH, Chen YP, Zhou GQ, Wei C, Liang XY, Zhang Y, Zhang CJ, He SW, He QM, Huang ZL, Guan JL, Shen JY, Li XM, Li JY, Li WF, Tang LL, Mao YP, Guo R, Sun R, Zheng YH, Zhou WW, Xiong KX, Wang SQ, Jin X, Liu N, Li GB, Kuang DM, Sun Y, Ma J (Corresponding author). The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023;29(6):1424-1436. (IF 58.7)
7. Lv J, Xu LX, Li ZX, Lin L, Wu CF, Quan TQ, Zhen ZC, Li WF, Tang LL, Mao YP, Chen L, Guo R, Zhang LL, Ai XL, Wu SY, Hao MY, Wei DH, Li JB, Chen YP, Zhou GQ, Sun Y, Ma J (Corresponding author). Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study. Cancer Cell. 2024; 2024;42(8):1401-1414.e4. (IF 48.8)
8. Du XJ, Wang GY, Zhu XD, Han YQ, Lei F, Shen LF, Yang KY, Chen L, Mao YP, Tang LL, Li L, Wu Z, Xu GQ, Zhou Q, Huang J, Guo R, Zhang Y, Liu X, Zhou GQ, Li WF, Xu C, Lin L, Chen YP, Chen FP, Liang XY, Chen SY, Li SQ, Cui CY, Li JB, Ren J, Chen MY, Liu LZ, Sun Y, Ma J (Corresponding author). Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma. Cancer Cell. 2024 11;42(3):464-473. (IF 48.8)
9. Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JL, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, Lee AWM, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y, Ma J (Corresponding author). Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021;39(7):840-859. (IF 42.1)
10. Tang LL, Huang CL, Zhang N, Jiang W, Wu YS, Huang SH, Mao YP, Liu Q, Li JB, Liang SQ, Qin GJ, Hu WH, Sun Y, Xie FY, Chen L, Zhou GQ, Ma J (Corresponding author). Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022;23(4):479-490. (IF 41.6)